Maravai LifeSciences Reports Second Quarter 2025 Financial Results

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings

Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year

Read more at globenewswire.com